Intellia Therapeutics NTLA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$394.6M+4.4% | -$412.69M+7.4% | -$445.81M+7.2% | -$480.19M+8.7% | -$525.91M-1.3% | ||
| $9.48M-3.0% | $9.78M-1.9% | $9.96M-2.0% | $10.16M-1.0% | $10.26M-0.1% | ||
| $71.86M-10.4% | $80.22M-22.2% | $103.1M-16.3% | $123.11M-13.3% | $141.94M-8.0% | ||
| —— | —— | —— | -$975K+96.2% | -$25.92M+7.2% | ||
| $6.44M+7.5% | $5.99M+1,190% | $464K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $39.54M+50.1% | $26.35M+53.9% | $17.12M+202% | -$16.8M-18.7% | -$14.15M-173% | ||
| -$29.68M-5.6% | -$28.11M-40.7% | -$19.98M+2.8% | -$20.54M+5.8% | -$21.8M+1.2% | ||
| $1.22M— | $0+100% | -$429K+93.8% | -$6.93M+75.8% | -$28.63M+12.1% | ||
| -$363.15M+8.0% | -$394.74M+3.9% | -$410.65M+1.9% | -$418.58M-11.0% | -$377.15M-8.1% | ||
| $473K-58.1% | $1.13M-43.1% | $1.98M-38.7% | $3.23M-19.3% | $4.01M-30.7% | ||
| $200.75M-12.2% | $228.77M-35.2% | $352.8M+2.2% | $345.09M+61.3% | $213.99M+70.4% | ||
| —— | $128.18M-25.6% | $172.16M-0.9% | $173.76M-0.7% | $174.94M-1.1% | ||
| $165.06M+25.5% | $131.49M-0.3% | $131.83M+32.9% | $99.16M-21.1% | $125.76M-32.3% | ||
| —— | —— | —— | —— | —— | ||
| $4.11M-29.8% | $5.86M-32.2% | $8.63M-27.0% | $11.83M-20.1% | $14.81M-16.9% | ||
| $1.22M— | $0+100% | -$429K+93.8% | -$6.93M+75.8% | -$28.63M+12.1% | ||
| -$38.76M+29.5% | -$54.95M-0.7% | -$54.56M+0.1% | -$54.61M-28.4% | -$42.51M-137% | ||
| -$34.28M-3.6% | -$33.09M-6.0% | -$31.21M-12.9% | -$27.65M-16.5% | -$23.73M-10.6% | ||
| -$16.56M-489% | -$2.81M— | —— | —— | —— | ||
| $39.54M+50.1% | $26.35M+53.9% | $17.12M+202% | -$16.8M-18.7% | -$14.15M-173% | ||
| -$50K-256% | $32K-84.2% | $203K— | —— | —— | ||
| -$29.68M-5.6% | -$28.11M-40.7% | -$19.98M+2.8% | -$20.54M+5.8% | -$21.8M+1.2% | ||
| —— | $0-100% | $28.21M-50.0% | $56.41M-33.3% | $84.62M-25.0% | ||
| —— | —— | —— | —— | —— | ||
| -$363.63M+8.1% | -$395.87M+4.1% | -$412.63M+2.2% | -$421.82M-10.7% | -$381.16M-7.5% | ||
| -$363.63M+8.1% | -$395.87M+4.1% | -$412.63M+2.2% | -$421.82M-10.7% | -$381.16M-7.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Intellia Therapeutics generate?
- Intellia Therapeutics (NTLA) generated -$363.2M in operating cash flow over the trailing twelve months.
- What is Intellia Therapeutics's free cash flow?
- After $473.0K of capital expenditures, Intellia Therapeutics's free cash flow was -$363.6M over the trailing twelve months, up 4.6% year over year.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
